Next Generation Diabetes Therapy and Drug Delivery Market growth , analysis and opportunities by dominant key players Abbott Laboratories, Echo Therapeutics, Inc., F. Hoffmann-La Roche Ltd., GlySens Incorporated, Medtronic Plc, Sanofi, Novo Nordisk, MannK

According to a new report published by Allied Market Research, titled, Next Generation Diabetes Therapy and Drug Delivery Market by Product Type, Demographics, Indication, and End Users: U.S. Opportunity Analysis and Industry Forecast, 20142023," the U.S. next generation diabetes therapy and drug delivery market accounted for $446 million in 2015, and is estimated to reach $6,510 million by 2023, registering a CAGR of 33.0% from 2017 to 2023. Diagnostics/clinics is the dominant segment, accounting for a little less than half the share of the U.S. market in 2015.

Next generation diabetes therapy and drug delivery devices are the advanced form of diabetic products that help improve the quality of life of diabetic patients. Oral and inhalable insulin introduces a different mode of insulin delivery in diabetic patients. As compared to injectable insulins, oral and inhalable insulin are painless mode of introducing insulin and reduces the risk of skin irritation due to needles. With the advancements in diabetes therapy systems such as insulin patches, CGM systems, and artificial pancreas, these devices can frequently detect the glucose levels and adjust the insulin levels that need to be used to manage the variation in glucose levels

Get sample copy of this report:
https://www.alliedmarketresearch.com/request-sample/4621

Depending on demographics, the market is bifurcated into adult and child population. Adult population is the dominant segment that contributes toward the market growth as almost 90% of the diabetic population in the U.S. is above the age of 18 years.

Key Findings of the U.s. Next Generation Diabetes Therapy And Drug Delivery Market :

• The home healthcare segment is projected to grow at the highest rate during the analysis period.

• CGM system was the highest revenue contributor, and is expected to continue its dominance throughout the forecast period.

• Diagnostics/clinics dominated the U.S. next generation diabetes therapy and drug delivery market, and is projected to grow at a CAGR of 32.0%.

• Type II diabetes is the fastest growing segment in the U.S., registering a CAGR of 33.1%.

Get customized report at:
https://www.alliedmarketresearch.com/request-for-customization/4621

As compared to other diabetic products, CGM system is a well-established market and dominates the next generation diabetes therapy and drug delivery market. This is attributed to the presence of a large patient base suffering from diabetes and advantages of using these systems as compared to conventional diabetic products such as ease of usage, and efficient and early detection of change in blood glucose levels.

Key players:

• Abbott Laboratories
• Echo Therapeutics Inc.
• F. Hoffmann-La Roche Ltd.
• GlySens Incorporated
• Medtronic Plc
• Sanofi
• Novo Nordisk
• MannKind Corporation
• Dexcom Inc.
•Senseonics Holding Inc.

Table of content:

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets
3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year
3.2.2. Patent analysis by product

3.3. GOVERNMENT REGULATIONS

3.3.1. U.S. FDA

3.4. REIMBURSEMENT POLICIES
3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.5.1. Smart contact lenses for glucose monitoring
3.5.2. iLet bihormonal bionic pancreas
3.5.3. Glucose nanosensors
3.5.4. Beta cell replacement therapy
3.5.5. Glucose-responsive insulin-producing cells

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence of diabetes
3.6.1.2. Rise in healthcare expenditure & disposable income
3.6.1.3. Benefits of using next generation diabetes products over conventional products

3.6.2. Restraints

3.6.2.1. Cost restrains
3.6.2.2. Lack of awareness
3.6.2.3. Less variability in products

3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs
3.6.3.2. High undiagnosed diabetic patient population

Access full summary at: https://www.alliedmarketresearch.com/U-S-next-generation-diabetes-therapy-and-drug-delivery-market

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.